The trial will evaluate the safety and efficacy of HuCNS-SC cells as a treatment for dry AMD. These cells are a purified population of human neural stem cells that can self-renew and differentiate into the three major cell types. Currently, there is no approved treatment for dry AMD.
Related Articles on Ophthalmology:
Ophthalmologists Have More Musculoskeletal Disorders Than Other Physicians
Researchers Find Simple Surgery Fixes Crossed Eyes
FDA Approves Mobius Therapeutics’ Glaucoma Drug
